Photocure ASA - Invitation to presentation of new commercial strategy
INVITATION TO PRESENTATION OF NEW COMMERCIAL HEXVIX STRATEGY
Oslo, Norway, 27 September, 2011: Photocure ASA (OSE: PHO) invites to a presentation of the new commercial strategy for Hexvix® on Tuesday 27 September at 11:00 CET, Hotel Continental, Stortingsgaten 24/26, Oslo.
The presentation will be held by President & CEO, Kjetil Hestdal and COO Kathleen Deardorff.
The presentation will be made available at www.photocure.no and can be followed real time on http://webtv.hegnar.no/webcast.php?id=33388
Best regards,
Photocure ASA
Christian Fekete
CFO
About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.
Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act
